Table 2 Baseline characteristics among Scar groups at the time of CABG
Parameter | <4 segments - Group A (Mean/Median (IQ)/% | ≥4 segments - Group B Mean/Median (IQ)/% | p value |
|---|---|---|---|
Number | 67 | 66 | |
Age (Years) | 63.3 (11.2) | 62.3 (13.2) | 0.69 |
Male (%) | 76.1 | 80.3 | 0.56 |
Body Mass Index (BMI) | 28.4 (4.7) | 28.4 (4.9) | 0.98 |
History Of Smoking (%) | 62.7 | 68.2 | 0.51 |
Diabetes Mellitus (%) | 38.8 | 37.9 | 0.91 |
Hypertension (%) | 79.1 | 78.8 | 0.97 |
History of Prior MI (%) | 74.6 | 72.7 | 0.81 |
Cerebrovascular Disease (%) | 14.9 | 12.1 | 0.64 |
Peripheral artery disease (%) | 14.9 | 22.7 | 0.25 |
Dyslipidemia (%) | 71.6 | 74.2 | 0.74 |
Previous CABG (%) | 1.5 | 13.6 | 0.009 |
Glomerular filtration rate (GFR) | 68.9 (22.0) | 69.6 (28.0) | 0.87 |
Chronic Lung Disease (%) | 19.4 | 13.6 | 0.37 |
B – Blocker (%) | 85.1 | 77.3 | 0.2495 |
ACE - Inhibitor (%) | 70.2 | 47.0 | 0.0066 |
Aspirin (%) | 92.5 | 93.9 | 1.000 |
Lipid Lowering Therapy (%) | 68.4 | 83.3 | 0.0914 |
LVEDV (ml) | 206.8 (73.5) | 226.7 (73.0) | 0.1237 |
LVESV (ml) | 129.4 (71.6) | 151.3 (72.9) | 0.0847 |
LVEF(%) | 39 (28,52) | 35 (26,45) | 0.12 |
Number of Segments scar | 2 (1,3) | 6 (5,7) | <0.0001 |
Number of trans mural segments | 1 (0, 2) | 2 (1,5) | <0.0001 |
Scar score | 1.19 (1.13,1.25) | 1.50 (1.38,1.75) | <0.0001 |
STS % mortality risk | 1.40 (0.66,3.59) | 1.46 (0.79,2.69) | 0.90 |
Cardiopulmonary Bypass Used (%) | 62.7 | 66.7 | 0.6312 |
Number of vessels bypassed | 4 (2–5) | 3 (3–4) | 0.5929 |